EP2023944A2 - Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice - Google Patents
Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic miceInfo
- Publication number
- EP2023944A2 EP2023944A2 EP07776079A EP07776079A EP2023944A2 EP 2023944 A2 EP2023944 A2 EP 2023944A2 EP 07776079 A EP07776079 A EP 07776079A EP 07776079 A EP07776079 A EP 07776079A EP 2023944 A2 EP2023944 A2 EP 2023944A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- animal
- transgenic
- transgenic non
- seq
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091033773 MiR-155 Proteins 0.000 title claims abstract description 38
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 title claims description 29
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 title claims description 21
- 230000004663 cell proliferation Effects 0.000 title claims description 11
- 238000011830 transgenic mouse model Methods 0.000 title description 61
- 241000699660 Mus musculus Species 0.000 title description 42
- 208000003747 lymphoid leukemia Diseases 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 143
- 230000009261 transgenic effect Effects 0.000 claims abstract description 100
- 241001465754 Metazoa Species 0.000 claims abstract description 74
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 51
- 230000001105 regulatory effect Effects 0.000 claims abstract description 48
- 230000014509 gene expression Effects 0.000 claims abstract description 44
- 230000001589 lymphoproliferative effect Effects 0.000 claims abstract description 44
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 41
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 40
- 230000002103 transcriptional effect Effects 0.000 claims abstract description 38
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 35
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 35
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 16
- 238000010998 test method Methods 0.000 claims abstract description 4
- 210000000952 spleen Anatomy 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 35
- 230000036210 malignancy Effects 0.000 claims description 27
- 210000001185 bone marrow Anatomy 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 210000004698 lymphocyte Anatomy 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 24
- 239000003623 enhancer Substances 0.000 claims description 23
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 20
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 19
- 208000024891 symptom Diseases 0.000 claims description 18
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 206010041660 Splenomegaly Diseases 0.000 claims description 8
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims description 8
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 7
- 206010025327 Lymphopenia Diseases 0.000 claims description 7
- 210000001015 abdomen Anatomy 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 231100001023 lymphopenia Toxicity 0.000 claims description 7
- 208000012526 B-cell neoplasm Diseases 0.000 claims description 6
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 5
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 4
- 108091034057 RNA (poly(A)) Proteins 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000007541 Preleukemia Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 2
- 239000002299 complementary DNA Substances 0.000 description 77
- 241000699666 Mus <mouse, genus> Species 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 19
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 18
- 108700019146 Transgenes Proteins 0.000 description 18
- 230000035755 proliferation Effects 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 239000002679 microRNA Substances 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 14
- 108091070501 miRNA Proteins 0.000 description 14
- 108700011259 MicroRNAs Proteins 0.000 description 13
- 210000004988 splenocyte Anatomy 0.000 description 13
- 210000000265 leukocyte Anatomy 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 238000002493 microarray Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 238000002105 Southern blotting Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 101150008989 55 gene Proteins 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000001000 micrograph Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010039435 NK Cell Lectin-Like Receptors Proteins 0.000 description 4
- 102000015223 NK Cell Lectin-Like Receptors Human genes 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091006112 ATPases Proteins 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 208000004736 B-Cell Leukemia Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102100024348 Beta-adducin Human genes 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 102100031158 GAS2-like protein 3 Human genes 0.000 description 3
- 101000689619 Homo sapiens Beta-adducin Proteins 0.000 description 3
- 101001066167 Homo sapiens GAS2-like protein 3 Proteins 0.000 description 3
- 108091068661 Mus musculus miR-155 stem-loop Proteins 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000002559 cytogenic effect Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- BSDCIRGNJKZPFV-GWOFURMSSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(2,5,6-trichlorobenzimidazol-1-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=CC(Cl)=C(Cl)C=C2N=C1Cl BSDCIRGNJKZPFV-GWOFURMSSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000001805 Bromodomains Human genes 0.000 description 2
- 108050009021 Bromodomains Proteins 0.000 description 2
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 2
- 108010009575 CD55 Antigens Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 description 2
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 description 2
- 206010061764 Chromosomal deletion Diseases 0.000 description 2
- 208000016718 Chromosome Inversion Diseases 0.000 description 2
- 108050001175 Connexin Proteins 0.000 description 2
- 102000010970 Connexin Human genes 0.000 description 2
- 102000011087 DEP domains Human genes 0.000 description 2
- 108050001299 DEP domains Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 102100033484 DNA repair and recombination protein RAD54-like Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 102000009331 Homeodomain Proteins Human genes 0.000 description 2
- 108010048671 Homeodomain Proteins Proteins 0.000 description 2
- 101000712511 Homo sapiens DNA repair and recombination protein RAD54-like Proteins 0.000 description 2
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 2
- 101000763322 Homo sapiens M1-specific T cell receptor beta chain Proteins 0.000 description 2
- 101001120794 Homo sapiens Opioid growth factor receptor-like protein 1 Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 101000763321 Homo sapiens T cell receptor beta chain MC.7.G5 Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 102100037874 Intercellular adhesion molecule 4 Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108010033242 Kynurenine 3-monooxygenase Proteins 0.000 description 2
- 102100037652 Kynurenine 3-monooxygenase Human genes 0.000 description 2
- 102100039564 Leukosialin Human genes 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102000016397 Methyltransferase Human genes 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 108010001621 NK Cell Lectin-Like Receptor Subfamily A Proteins 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 102100026074 Opioid growth factor receptor-like protein 1 Human genes 0.000 description 2
- 102000016304 Origin Recognition Complex Human genes 0.000 description 2
- 108010067244 Origin Recognition Complex Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102100039300 Phosphatidylserine synthase 2 Human genes 0.000 description 2
- 101710116267 Phosphatidylserine synthase 2 Proteins 0.000 description 2
- 102100038121 Phospholipid phosphatase 1 Human genes 0.000 description 2
- 101710117878 Phospholipid phosphatase 1 Proteins 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 102100024447 Prostaglandin E2 receptor EP3 subtype Human genes 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 101710098761 Protein alpha-1 Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102100038475 Rab-3A-interacting protein Human genes 0.000 description 2
- 101710201694 Rab-3A-interacting protein Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108091006207 SLC-Transporter Proteins 0.000 description 2
- 102000037054 SLC-Transporter Human genes 0.000 description 2
- 108090000184 Selectins Proteins 0.000 description 2
- 102000003800 Selectins Human genes 0.000 description 2
- 102000044463 Septin 8 Human genes 0.000 description 2
- 108700036698 Septin 8 Proteins 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 102100026967 T cell receptor beta chain MC.7.G5 Human genes 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 2
- 108010023649 Tripartite Motif Proteins Proteins 0.000 description 2
- 102000011408 Tripartite Motif Proteins Human genes 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 241000269368 Xenopus laevis Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- -1 antibodies) Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000003969 blast cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000003976 gap junction Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 2
- 108040001860 guanyl-nucleotide exchange factor activity proteins Proteins 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000005004 lymphoid follicle Anatomy 0.000 description 2
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JBFQOLHAGBKPTP-NZATWWQASA-N (2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](N)CCCCN JBFQOLHAGBKPTP-NZATWWQASA-N 0.000 description 1
- VSKBNXJTZZAEPH-NSEZLWDYSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O VSKBNXJTZZAEPH-NSEZLWDYSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- 101150025032 13 gene Proteins 0.000 description 1
- 101150101112 7 gene Proteins 0.000 description 1
- 108050003506 ABL interactor 2 Proteins 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 102100022936 ATPase inhibitor, mitochondrial Human genes 0.000 description 1
- 101710085568 ATPase inhibitor, mitochondrial Proteins 0.000 description 1
- 102100028221 Abl interactor 2 Human genes 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 101710200145 Acyl-CoA 6-desaturase Proteins 0.000 description 1
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 102100039736 Adhesion G protein-coupled receptor L1 Human genes 0.000 description 1
- 108010058060 Alanine-tRNA ligase Proteins 0.000 description 1
- 102100037399 Alanine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102100022299 All trans-polyprenyl-diphosphate synthase PDSS1 Human genes 0.000 description 1
- 102100034452 Alternative prion protein Human genes 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 102100031366 Ankyrin-1 Human genes 0.000 description 1
- 101710191059 Ankyrin-1 Proteins 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010024284 Apolipoprotein C-II Proteins 0.000 description 1
- 102100039998 Apolipoprotein C-II Human genes 0.000 description 1
- 102000018757 Apolipoprotein L1 Human genes 0.000 description 1
- 108010052469 Apolipoprotein L1 Proteins 0.000 description 1
- 102100022108 Aspartyl/asparaginyl beta-hydroxylase Human genes 0.000 description 1
- 101710140787 Aspartyl/asparaginyl beta-hydroxylase Proteins 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 1
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 1
- 102000009039 Axonemal Dyneins Human genes 0.000 description 1
- 108010049197 Axonemal Dyneins Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- 101710083734 CTP synthase Proteins 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100032145 Carbohydrate sulfotransferase 10 Human genes 0.000 description 1
- 101710096630 Carbohydrate sulfotransferase 10 Proteins 0.000 description 1
- 108090000018 Carboxypeptidase D Proteins 0.000 description 1
- 102100032407 Carboxypeptidase D Human genes 0.000 description 1
- 102100029391 Cardiotrophin-like cytokine factor 1 Human genes 0.000 description 1
- 101710107109 Cardiotrophin-like cytokine factor 1 Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100024478 Cell division cycle-associated protein 2 Human genes 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000017589 Chromo domains Human genes 0.000 description 1
- 108050005811 Chromo domains Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102100028796 Chromosome transmission fidelity protein 18 homolog Human genes 0.000 description 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010037663 Cortactin Proteins 0.000 description 1
- 102000010958 Cortactin Human genes 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 102100032759 Cysteine-rich motor neuron 1 protein Human genes 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- 102100025269 DENN domain-containing protein 2B Human genes 0.000 description 1
- 101710141585 DENN domain-containing protein 2B Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100029903 DNA polymerase epsilon catalytic subunit A Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 101100412663 Danio rerio rasgef1bb gene Proteins 0.000 description 1
- 102100030220 Diacylglycerol kinase zeta Human genes 0.000 description 1
- 101710192015 Diacylglycerol kinase zeta Proteins 0.000 description 1
- 102100029721 DnaJ homolog subfamily B member 1 Human genes 0.000 description 1
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 description 1
- 102000015699 E2F1 Transcription Factor Human genes 0.000 description 1
- 108010063774 E2F1 Transcription Factor Proteins 0.000 description 1
- 102000005628 E2F7 Transcription Factor Human genes 0.000 description 1
- 108010059718 E2F7 Transcription Factor Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100035087 Ectoderm-neural cortex protein 1 Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 101710172058 Ependymin-related protein 2 Proteins 0.000 description 1
- 102100037255 Equilibrative nucleobase transporter 1 Human genes 0.000 description 1
- 241001226424 Erato <angiosperm> Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 102100029075 Exonuclease 1 Human genes 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 102100040650 F-BAR and double SH3 domains protein 2 Human genes 0.000 description 1
- 101710177999 Fatty acid desaturase 2 Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 101150066968 GPR183 gene Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102100033962 GTP-binding protein RAD Human genes 0.000 description 1
- 102100024412 GTPase IMAP family member 4 Human genes 0.000 description 1
- 102100024413 GTPase IMAP family member 5 Human genes 0.000 description 1
- 102100024422 GTPase IMAP family member 7 Human genes 0.000 description 1
- 102100034004 Gamma-adducin Human genes 0.000 description 1
- 102100021023 Gamma-glutamyl hydrolase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 102100030430 Group XIIA secretory phospholipase A2 Human genes 0.000 description 1
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 102100025110 Homeobox protein Hox-A5 Human genes 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000980905 Homo sapiens Cell division cycle-associated protein 2 Proteins 0.000 description 1
- 101000916387 Homo sapiens Chromosome transmission fidelity protein 18 homolog Proteins 0.000 description 1
- 101000942095 Homo sapiens Cysteine-rich motor neuron 1 protein Proteins 0.000 description 1
- 101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 1
- 101000864180 Homo sapiens DNA polymerase epsilon catalytic subunit A Proteins 0.000 description 1
- 101001057621 Homo sapiens Dual specificity protein phosphatase 4 Proteins 0.000 description 1
- 101000877456 Homo sapiens Ectoderm-neural cortex protein 1 Proteins 0.000 description 1
- 101000740107 Homo sapiens Equilibrative nucleobase transporter 1 Proteins 0.000 description 1
- 101000892420 Homo sapiens F-BAR and double SH3 domains protein 2 Proteins 0.000 description 1
- 101001132495 Homo sapiens GTP-binding protein RAD Proteins 0.000 description 1
- 101000833375 Homo sapiens GTPase IMAP family member 4 Proteins 0.000 description 1
- 101000833376 Homo sapiens GTPase IMAP family member 5 Proteins 0.000 description 1
- 101000833390 Homo sapiens GTPase IMAP family member 7 Proteins 0.000 description 1
- 101000799011 Homo sapiens Gamma-adducin Proteins 0.000 description 1
- 101001126622 Homo sapiens Group XIIA secretory phospholipase A2 Proteins 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101001077568 Homo sapiens Homeobox protein Hox-A5 Proteins 0.000 description 1
- 101000854886 Homo sapiens Immunoglobulin iota chain Proteins 0.000 description 1
- 101000599868 Homo sapiens Intercellular adhesion molecule 4 Proteins 0.000 description 1
- 101001091266 Homo sapiens Kinesin-like protein KIF13A Proteins 0.000 description 1
- 101001050567 Homo sapiens Kinesin-like protein KIF2C Proteins 0.000 description 1
- 101001121408 Homo sapiens L-amino-acid oxidase Proteins 0.000 description 1
- 101000721380 Homo sapiens OTU domain-containing protein 1 Proteins 0.000 description 1
- 101000904196 Homo sapiens Pancreatic secretory granule membrane major glycoprotein GP2 Proteins 0.000 description 1
- 101000911588 Homo sapiens Protein FAM169B Proteins 0.000 description 1
- 101000928406 Homo sapiens Protein diaphanous homolog 3 Proteins 0.000 description 1
- 101000588033 Homo sapiens Protein spire homolog 1 Proteins 0.000 description 1
- 101000702384 Homo sapiens Protein sprouty homolog 2 Proteins 0.000 description 1
- 101000831286 Homo sapiens Protein timeless homolog Proteins 0.000 description 1
- 101000651439 Homo sapiens Prothrombin Proteins 0.000 description 1
- 101000707471 Homo sapiens Serine incorporator 3 Proteins 0.000 description 1
- 101001041365 Homo sapiens Serine protease HTRA2, mitochondrial Proteins 0.000 description 1
- 101000780111 Homo sapiens Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A Proteins 0.000 description 1
- 101000632529 Homo sapiens Shugoshin 1 Proteins 0.000 description 1
- 101000688543 Homo sapiens Shugoshin 2 Proteins 0.000 description 1
- 101000640831 Homo sapiens Sodium-coupled neutral amino acid transporter 5 Proteins 0.000 description 1
- 101000802055 Homo sapiens THUMP domain-containing protein 2 Proteins 0.000 description 1
- 101000662997 Homo sapiens TRAF2 and NCK-interacting protein kinase Proteins 0.000 description 1
- 101000830894 Homo sapiens Targeting protein for Xklp2 Proteins 0.000 description 1
- 101000766349 Homo sapiens Tribbles homolog 2 Proteins 0.000 description 1
- 101000759984 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 46 Proteins 0.000 description 1
- 101000772904 Homo sapiens Ubiquitin-conjugating enzyme E2 D1 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100020744 Immunoglobulin iota chain Human genes 0.000 description 1
- 102000000426 Integrin alpha6 Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 101710148793 Intercellular adhesion molecule 4 Proteins 0.000 description 1
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 description 1
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 description 1
- 108010028784 Interleukin-18 Receptor alpha Subunit Proteins 0.000 description 1
- 102100039340 Interleukin-18 receptor 1 Human genes 0.000 description 1
- 102000010682 Interleukin-9 Receptors Human genes 0.000 description 1
- 108010038414 Interleukin-9 Receptors Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000009875 Ki-67 Antigen Human genes 0.000 description 1
- 108010020437 Ki-67 Antigen Proteins 0.000 description 1
- 102100034865 Kinesin-like protein KIF13A Human genes 0.000 description 1
- 102100023424 Kinesin-like protein KIF2C Human genes 0.000 description 1
- 102100026388 L-amino-acid oxidase Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000008201 Lamin Type A Human genes 0.000 description 1
- 108010021099 Lamin Type A Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 108050008782 Latrophilin-1 Proteins 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 108091034054 MiR-138 Proteins 0.000 description 1
- 108091093082 MiR-146 Proteins 0.000 description 1
- 108091028695 MiR-224 Proteins 0.000 description 1
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 description 1
- 108020002334 Monoacylglycerol lipase Proteins 0.000 description 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100129378 Mus musculus Marchf8 gene Proteins 0.000 description 1
- 108091068686 Mus musculus miR-151 stem-loop Proteins 0.000 description 1
- 108091067719 Mus musculus miR-182 stem-loop Proteins 0.000 description 1
- 108091067688 Mus musculus miR-201 stem-loop Proteins 0.000 description 1
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 description 1
- 108091007369 NEUR proteins Proteins 0.000 description 1
- 108010084810 Neurotransmitter Transport Proteins Proteins 0.000 description 1
- 102000005665 Neurotransmitter Transport Proteins Human genes 0.000 description 1
- 102100023731 Noelin Human genes 0.000 description 1
- 101710157449 Noelin Proteins 0.000 description 1
- 102100021133 Nuclear protein 1 Human genes 0.000 description 1
- 101710170054 Nuclear protein 1 Proteins 0.000 description 1
- 102100025195 OTU domain-containing protein 1 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 102100024019 Pancreatic secretory granule membrane major glycoprotein GP2 Human genes 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 1
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 102100034627 Phospholipid scramblase 1 Human genes 0.000 description 1
- 101710149609 Phospholipid scramblase 1 Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 108010049395 Prokaryotic Initiation Factor-2 Proteins 0.000 description 1
- 101710125002 Prostaglandin E2 receptor EP3 subtype Proteins 0.000 description 1
- 102100026935 Protein FAM169B Human genes 0.000 description 1
- 108010003506 Protein Kinase D2 Proteins 0.000 description 1
- 102000006478 Protein Phosphatase 2 Human genes 0.000 description 1
- 108010058956 Protein Phosphatase 2 Proteins 0.000 description 1
- 102100036468 Protein diaphanous homolog 3 Human genes 0.000 description 1
- 102100031617 Protein spire homolog 1 Human genes 0.000 description 1
- 102100030400 Protein sprouty homolog 2 Human genes 0.000 description 1
- 102100024287 Protein timeless homolog Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 102000015176 Proton-Translocating ATPases Human genes 0.000 description 1
- 108010039518 Proton-Translocating ATPases Proteins 0.000 description 1
- 102100031535 RAD51-associated protein 1 Human genes 0.000 description 1
- 101710182832 RAD51-associated protein 1 Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102000028598 Rab30 Human genes 0.000 description 1
- 108050007282 Rab30 Proteins 0.000 description 1
- 102100035778 Regulator of G-protein signaling 11 Human genes 0.000 description 1
- 101710148336 Regulator of G-protein signaling 11 Proteins 0.000 description 1
- 101710191757 Resistin-like alpha Proteins 0.000 description 1
- 102100020899 Rho GTPase-activating protein 29 Human genes 0.000 description 1
- 101710110344 Rho GTPase-activating protein 29 Proteins 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100031727 Serine incorporator 3 Human genes 0.000 description 1
- 102100021117 Serine protease HTRA2, mitochondrial Human genes 0.000 description 1
- 102100037312 Serine/threonine-protein kinase D2 Human genes 0.000 description 1
- 102100034285 Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A Human genes 0.000 description 1
- 102100036292 Short coiled-coil protein Human genes 0.000 description 1
- 101710167856 Short coiled-coil protein Proteins 0.000 description 1
- 102100028402 Shugoshin 1 Human genes 0.000 description 1
- 102100024238 Shugoshin 2 Human genes 0.000 description 1
- 108010041218 Sirtuin 3 Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102100033872 Sodium-coupled neutral amino acid transporter 5 Human genes 0.000 description 1
- 108010019965 Spectrin Proteins 0.000 description 1
- 102000005890 Spectrin Human genes 0.000 description 1
- 102100021915 Sperm-associated antigen 5 Human genes 0.000 description 1
- 101710098571 Sperm-associated antigen 5 Proteins 0.000 description 1
- 102100039024 Sphingosine kinase 1 Human genes 0.000 description 1
- 101710119798 Stearoyl-CoA desaturase 2 Proteins 0.000 description 1
- 102000004896 Sulfotransferases Human genes 0.000 description 1
- 108090001033 Sulfotransferases Proteins 0.000 description 1
- 102100026939 Suppressor of fused homolog Human genes 0.000 description 1
- 101710106589 Suppressor of fused homolog Proteins 0.000 description 1
- 102000019355 Synuclein Human genes 0.000 description 1
- 108050006783 Synuclein Proteins 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100034705 THUMP domain-containing protein 2 Human genes 0.000 description 1
- 102100037671 TRAF2 and NCK-interacting protein kinase Human genes 0.000 description 1
- 102100024813 Targeting protein for Xklp2 Human genes 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102000012607 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 102100034686 Tight junction protein ZO-1 Human genes 0.000 description 1
- 108050001370 Tight junction protein ZO-1 Proteins 0.000 description 1
- 101710158136 Trans-prenyltransferase Proteins 0.000 description 1
- 102100026394 Tribbles homolog 2 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100025025 Ubiquitin carboxyl-terminal hydrolase 46 Human genes 0.000 description 1
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 1
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 1
- 102100030433 Ubiquitin-conjugating enzyme E2 D1 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000006254 Wolf-Hirschhorn Syndrome Diseases 0.000 description 1
- 102100021360 Zinc finger protein 260 Human genes 0.000 description 1
- 101710143808 Zinc finger protein 260 Proteins 0.000 description 1
- 102100026332 Zinc finger protein 277 Human genes 0.000 description 1
- 101710143867 Zinc finger protein 277 Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002244 anti-lymphoproliferative effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000009015 carbon catabolite repression of transcription Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 108090000047 fibroblast growth factor 13 Proteins 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011368 intensive chemotherapy Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 210000002202 late pro-b cell Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 108091030496 miR-138 stem-loop Proteins 0.000 description 1
- 108091057645 miR-15 stem-loop Proteins 0.000 description 1
- 108091072763 miR-151 stem-loop Proteins 0.000 description 1
- 108091074057 miR-16-1 stem-loop Proteins 0.000 description 1
- 108091054642 miR-194 stem-loop Proteins 0.000 description 1
- 108091035328 miR-217 stem-loop Proteins 0.000 description 1
- 108091039135 miR-217-1 stem-loop Proteins 0.000 description 1
- 108091029206 miR-217-2 stem-loop Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 210000001586 pre-b-lymphocyte Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102000007268 rho GTP-Binding Proteins Human genes 0.000 description 1
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 108010035597 sphingosine kinase Proteins 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 108010022412 splicing factor 3a Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
Definitions
- Acute leukemia is a rapidly progressive malignant disease of the bone marrow and blood that results in the accumulation of immature, fiinctionless cells, called blast cells, in the marrow and blood.
- blast cells immature, fiinctionless cells
- the accumulation of blast cells in the marrow blocks normal blood cell development. As a result, red cells, white cells and platelets are not produced in sufficient numbers.
- ALL acute lymphoblastic leukemia
- AML acute myelogenous leukemia
- ALL is a rapidly progressive cancer that starts by the malignant transformation of a marrow lymphocyte.
- ALL is the most common type of childhood leukemia, with 3,000 new cases per year in all age groups.
- the transformed, now malignant, cell multiplies and accumulates in the marrow as leukemic lymphoblasts.
- the lymphoblasts block normal blood cell-formation in the marrow, resulting in insufficient production of red cells, white cells and platelets.
- High-grade lymphomas also known as aggressive lymphoma, include several subtypes of lymphoma that progress relatively rapidly if untreated. These subtypes include, e.g., AIDS-associated lymphoma, anaplastic large cell lymphoma, Burkitt's lymphoma, diffuse large cell lymphoma, immunoblastic lymphoma, lymphoblastic lymphoma and small noncleaved cell lymphomas. Compared to diffuse large B ⁇ cell lymphomas, high-grade lymphomas behave more aggressively, require more intensive chemotherapy, and occur more often in children. Because rapidly dividing cells are more sensitive to anti-cancer agents and because the young patients usually lack other health problems, some of these lymphomas show a dramatic response to therapy. Acute lymphoblastic leukemia and high-grade lymphoma are the most common leukemias and lymphomas in children. These diseases are, for the most part, polyclonal, suggesting that only a few genetic changes are sufficient to induce malignancy.
- MicroRNAs represent a new class of abundant small RNAs that play important regulatory roles at the post-transcriptional level by binding to targeted mRNAs and either blocking their translation or initiating their degradation, according to the degree of complementarity with the target. Since their discovery in 1993 in Caenorhabditis elegans (Lee, R. et al., Cell 75:843-854 (1993)), there have been numerous reports that implicated these tiny molecules in the posttranscriptional regulation of a large array of proteins with very diverse roles, ranging from cell proliferation and differentiation to lipid metabolism (Nairz, K., et al., Dev. Biol. 291:314-324 (2006); Chen, J.F., etal, Nat.
- m ⁇ RNA profiling of hematopoietic lineages in humans and mice showed that miRNAs are differentially expressed in the course of hematopoietic development, suggesting a potential role in hematopoietic differentiation (Chen, C.Z., et al, Science 303:83-86 (2004); Chen, C.Z., et al., Semin. Immunol. 77:155-165 (2005); and Ramkissoon, S.H., et al, Leuk. Res. 30:643-647 (2006)).
- miR-15 ' a and miR-16-1 are deleted or down-regulated in 68% of cases of chronic lymphocytic leukemia (CLL) (Calin, G.A., et al, Proc. Natl Acad Sci. USA 99: 15524-15529 (2002); and Calin, G.A., et al, Proc. Natl Acad. ScL USA 101:U755- ⁇ 1760 (2004)), and that miRNAs genes are frequently located at fragile sites and genomic regions involved in cancers (Calin, G.A., etal, Proc. Natl. Acad. Sci. USA 101:2999-3004 (2004)).
- CLL chronic lymphocytic leukemia
- miR155 and BIC (its host gene) transcripts have been shown to accumulate in human B cell lymphomas, especially diffuse large B cell lymphomas (Eis, P.S., et al, Proc. Natl Acad. ScL USA /02:3627-3632 (2005)), Hodgkin lymphomas (Kluvier, J., etal, J. Pathol 207:243-249 (2006)), and certain types of Burkitt lymphomas (latency type III Epstein- Barr virus-positive Burkitt lymphoma) (Kluvier, J., et al, Genes Chromosomes Cancer 45:147-153 (2006)).
- B cell malignancies e.g., B cell leukemias, B cell lymphomas.
- the present invention is based on the discovery that transgenic mice carrying a miRl 55 transgene, whose expression is targeted to B cells (e.g., using an Ig heavy chain- E ⁇ enhancer), initially exhibit a preleukemic pre-B cell proliferation, evident in spleen and bone marrow, and later develop B cell malignancies.
- Transgenic mice that overexpress miRl 55 develop a lymphoproliferative disease resembling human lymphoproliferative diseases, thus strongly implicating miRl 55 in the initiation and/or progression of these diseases.
- lymphoproliferative disorders such as B cell malignancies (e.g., acute lymphoblastic leukemia, high-grade lymphomas) in humans.
- B cell malignancies e.g., acute lymphoblastic leukemia, high-grade lymphomas
- novel animal models for lymphoproliferative disorders e.g., animal models for B cell malignancies (e.g., Ieukemias (e.g., acute lymphoblastic leukemia), lymphomas (e.g., high-grade lymphoma), and neoplasms) are provided.
- a transgenic non-human animal e.g., a mouse
- a transgenic non-human animal e.g., a mouse
- the miRl 55 gene product comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:1 and/or SEQ ID NO:2.
- the miRl 55 gene product comprises the nucleotide sequence of SEQ ID NO:1.
- the miRl 55 gene product comprises the nucleotide sequence of SEQ ID NO:2.
- the at least one transcriptional regulatory sequence can be any sequence capable of directing expression in B cells of the animal.
- the transcriptional regulatory sequence comprises a V H promoter (e.g., a V H promoter derived from mouse).
- the transcriptional regulatory sequence comprises an Ig heavy chain-E ⁇ enhancer (e.g., an Ig heavy chain-E ⁇ enhancer derived from mouse).
- the nucleic acid construct comprises the 3' UTR and poly(A) sequence of a ⁇ -globin gene (e.g., a ⁇ -globin gene derived from human or other mammalian species).
- transgenic non-human animal whose genome comprises a nucleic acid construct comprising a V H promoter and an Ig heavy chain-E ⁇ " enhancer, operably linked to a nucleic acid encoding a miR155 gene product comprising SEQ ID NO:1 and/or SEQ ID NO:2.
- the transgenic non- human animal's genome comprises a nucleic acid construct comprising a V H promoter and an Ig heavy chain-E ⁇ enhancer, operably linked to a nucleic acid encoding a miR155 gene product comprising a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:1 and/or SEQ ID NO:2.
- the transgenic non-human animal has an expanded population of B2201ow/CD19 low /CD10 low /IgMYTCR7CD43- lymphoid cells in the spleen, the bone marrow or both the spleen and bone marrow, relative to this population in a suitable control animal.
- the transgenic non-human animal exhibits a lymphoproliferative condition.
- the lymphoproliferative condition is a B cell malignancy (e.g., a B cell leukemia, for example, acute lymphoblastic leukemia; a B cell lymphoma, a B cell neoplasm).
- the B cell malignancy exhibits characteristics of human acute lymphoblastic leukemia, human lymphoblastic lymphoma or a combination thereof.
- the lymphoproliferative condition is a preleukemic state (e.g., pre-B cell proliferation).
- the transgenic non-human animal exhibits an enlarged abdomen, splenomegaly, bone marrow replacement, lymphopenia, or a combination thereof.
- the method comprises administering the agent to a transgenic non-human animal (e.g., a mouse) whose genome comprises a nucleic acid construct comprising at least one transcriptional regulatory sequence capable of directing expression in B cells of the animal (e.g., a V H promoter, an Ig heavy chain-E ⁇ enhancer, a combination thereof), wherein the transcriptional regulatory sequence is operably linked to a nucleic acid encoding a miR155 gene product comprising a nucleotide sequence having at least 90% sequence identity to SEQ ID NO: 1 and/or SEQ ID NO:2.
- a transgenic non-human animal e.g., a mouse
- a nucleic acid construct comprising at least one transcriptional regulatory sequence capable of directing expression in B cells of the animal (e.g., a V H promoter, an Ig heavy chain-E ⁇ enhancer, a combination thereof)
- the transcriptional regulatory sequence is operably linked to a nucleic acid encoding a miR155 gene product comprising
- the miR155 gene product comprises the nucleotide sequence of SEQ ID NO:1. In another embodiment, the miR155 gene product comprises the nucleotide sequence of SEQ ID NO:2. [00015] After the agent has been administered to the transgenic animal, one or more symptoms and/or indications of the lymphoproliferative condition in the transgenic animal are compared with those of a control animal of the same genotype, which has not been administered the agent. If the agent inhibits, prevents and/or reduces one or more symptoms and/or indications of the lymphoproliferative condition in the transgenic animal to which it has been administered, relative to the control animal, then the agent is considered to have therapeutic efficacy in treating or preventing a lymphoproliferative condition.
- the one or more symptoms and/or indications of the lymphoproliferative condition are selected from the group consisting of: an expanded population of B220 low /CD19 low /CD10 !ow / IgM7TCR7CD43 " lymphoid cells, an enlarged abdomen, splenomegaly, bone marrow replacement, lymphopenia and a combination thereof.
- a method of determining whether an agent affects a lymphoproliferative condition in a subject comprises administering an agent to a transgenic non-human animal described herein and comparing one or more symptoms and/or indications of the lymphoproliferative condition in the transgenic animal to those of a control animal of the same genotype, wherein the control animal has not been administered the agent.
- Detection of a difference in the detectability and/or rate of appearance of one or more symptoms and/or indications of the lymphoproliferative condition in the transgenic animal, relative to the control animal, is indicative of the agent affecting the lymphoproliferative condition.
- the lymphoproliferative condition is a B cell malignancy.
- the B cell malignancy is selected from the group consisting of acute lymphoblastic leukemia, B cell lymphoma (e.g., high-grade lymphoma), B cell neoplasm and a combination thereof.
- the B cell malignancy may exhibit characteristics of human acute lymphoblastic leukemia, human lymphoblastic lymphoma or both.
- the lymphoproliferative condition is a preleukemic state, such as a state characterized by pre-B cell proliferation.
- FIG. 1 is schematic diagram depicting the miR155 transgene construct that was injected in the male pronuclei of the oocytes of pregnant C57/B6 and FVB/N female mice.
- FIG. 2A is a Southern blot depicting the genotype of the seven miR155 transgenic founders (lanes 1, 3, 5, 6, 7, 10 and 14) and eight wild-type (lanes 2, 4, 8, 9, 11,
- FIG. 2B is a Southern blot depicting the genotype of eight miR155 transgenic founders (lanes 1, 3, 5, 7, 9, 11, 13 and 15) and seven wild-type (lanes 2, 4, 6, 8, 10, 12 and
- FIG. 3 is a Northern blot on total RNA depicting expression of mature miRl 55 in lymphocytes that were isolated from the spleens of 3-week-old mice from 6 of the 15 transgenic lines, using the antisense oligonucleotide of the mmu-miR155 mature sequence as a probe.
- the five transgenic lines with the highest level of expression of mature miRl 55 in the splenocytes were selected for further breeding and analysis.
- FIG. 4A is a photograph showing a transgenic mouse with a considerably enlarged abdomen (left), due to clinically-evident splenomegaly, relative to a wild-type mouse, at an age of 6 months.
- FIG. 4B is a photograph depicting the spleens of the mice shown in FIG. 4A.
- FIG. 5A is a micrograph depicting a hematoxylin/eosin (H&E)-stained section of spleen from a 3 week old transgenic mouse (mouse no. 50; founder no. 10) at 200 X magnification. The section displays atypical lymphoid proliferation compressing the white pulp.
- FIG. 5B is a micrograph depicting an H&E-stained section of spleen from a 6 month old trangenic mouse (founder no. 8) at 100 X magnification. The overall architecture of the spleen is being replaced by atypical lymphoid proliferation. Only a few germinal lymphoid follicles remain, which are greatly decreased in size and compressed by the proliferation.
- FlG. 5C is a micrograph depicting an H&E-stained section of spleen from a 6 month old trangenic mouse (founder no. 8) at 200 X magnification.
- the spleen architecture has been almost completely effaced by the lymphoblastic proliferation. • Remnants of 2 small compressed lymphoid follicles are visible.
- FIG. 5D is a micrograph depicting an H&E-stained section of bone marrow from a 6 month old trangenic mouse (founder no. 8) at 400 X magnification, showing the lymphoblastic proliferation in the bone marrow that leads to the replacement of the hemtopoietic foci.
- FIG. 5E is a micrograph depicting an H&E-stained section of normal spleen at 200 X magnification.
- FIG. 5F is a micrograph depicting a section of spleen from a 3 week old transgenic mouse (mouse no. 72) at 200 X magnification. The section has been stained for Ki67 and shows increased lymphoid proliferation in the spleen.
- FIG. 6 is a micrograph at 400 X magnification depicting atypical lymphoid proliferation in a section of spleen from a 3 week old transgenic mouse (mouse no. 50), which has been immunohistochemically-stained for IgM.
- IgM is present in the cytoplasm of the proliferating lymphocytes (clgM) as a brown perinuclear halo in the transgenic mice, whereas the wild-type lymphocytes are intensely brown, with no distinct nuclei, due to the presence of both slgM and clgM.
- FIG. 7A is a flow cytometry analysis profile depicting an expansion of a B220 low /CD19 low /CD10 low / ⁇ gM7TCR7CD43 " population of lymphocytes in the spleen of transgenic mice from two different lines of founders (founders 8 and 10). Gated splenocytes for two transgenic mice and two wild type mice at 3 weeks of age (transgenic mouse no. 74, founder 8 (74TG; upper left) and wild-type mouse no. 68 (68WT; upper right)) and 7 weeks of age (transgenic mouse no. 156, founder 10 (156TG; bottom left) and wild-type mouse no. 157 (157WT; bottom right)) are shown. Comparison of the upper left quadrants of the plots, gating the B220 + IgM population, shows an increase in the number of precursor B cells in the trangenic spleen, relative to wild type.
- FIG. 7B is a flow cytometry analysis profile depicting an expansion of a B220 low /CD19 low /CD10 low /IgM7TCRVCD43 " population of lymphocytes in the bone marrow of a transgenic mouse from founder 8.
- Gated bone marrow white blood cells for one transgenic and one wild-type mouse at 6 months of age (transgenic mouse no. 8, (8TG; left) and wild-type mouse no. 24 (24WT; right)) are shown. Comparison of the upper right quadrants of the two plots indicates a decrease in the B200 + IgM + gated mature B cell population of the bone marrow of the transgenic mouse, relative to the wild-type mouse.
- FIG. 8 A is a graph depicting B220-PE expression as evaluated by flow cytometry analysis on B220 + -gated splenocytes of wild-type mouse no.223 (223 WT) at 7 weeks of age.
- FIG. 8B is a graph depicting CDlO-FITC expression as evaluated by flow cytometry analysis on B220 + -gated splenocytes of wild-type mouse no. 223 (223 WT) at 7 weeks of age.
- FIG. 8C is a graph depicting B220-PE expression as evaluated by flow cytometry analysis on B220 + -gated splenocytes of transgenic mouse no. 222 (222TG) at 7 weeks of age, showing a noticeable increase in the B220 low population (intercalated between the two peaks of B220 " and B220 + ) in the transgenic mouse, relative to the wild-type mouse.
- FIG. 8D is a graph depicting CDl 0-FITC expression as evaluated by flow cytometry analysis on B220 + -gated splenocytes of transgenic mouse no. 222 (222TG) at 7 weeks of age, showing an increase in the percentage of the CDlO + population in the
- FIG. 8E is a graph depicting B220-PE expression as evaluated by flow cytometry analysis on B220 + -gated splenocytes of transgenic mouse no. 221 (221TG) at 7 weeks of age, showing a noticeable increase in the B220 low population (intercalated between the two peaks of B220 * and B220 + ) in the transgenic mouse, relative to the wild-type mouse.
- FIG. 8F is a graph depicting CDlO-FITC expression as evaluated by flow cytometry analysis on B220 + -gated splenocytes of transgenic mouse no. 221 (221TG) at 7 weeks of age, showing an increase in the percentage of the CDIO + population in the
- FIG. 9 is a karyotype of lymphoid cells isolated from a transgenic spleen, analyzed for chromosomal deletions, translocations and inversions, as well as the number of metaphases.
- the arrow indicates an abnormality in Chromosome 9, which was identified by the presence of a thick extra band.
- FIG. 10 is a Southern blot on DNA extracted from the splenocytes of 5 transgenic (TG) and 4 wild-type (WT) mice between 3 and 6 weeks of age. Southern blot hybridization was performed using the JH4 probe and different digesting enzymes, as indicated at the top of the lanes (Stul, BgIII, BamHI, and Hindlll). The thick bands of high molecular weight correspond to the germ line. There are no rearranged bands in the transgenic animals, relative to wild type.
- transgenic mice that overexpress the microRNA, miR155, develop a lymphoproliferative disease resembling acute lymphoblastic leukemia and high-grade lymphoma in humans.
- the results provided herein strongly indicate that oncogenic expression of miRl 55 and/or other gene(s) (e.g., genes that are activated in cancer (e.g., signal transduction genes)) are involved in the initiation and/or progression of B cell malignancies.
- an animal model that may be used to investigate the mechanisms underlying the initiation and progression of B cell malignancies and other lymphoproliferative conditions. This animal model may also be used in the identification, development and testing of novel therapeutic agents that are useful in treating or preventing lymphoproliferative disorders.
- transgenic animal whose genome comprises a nucleic acid construct or transgene comprising at least one transcriptional regulatory sequence capable of directing expression to B cells, wherein the transcriptional regulatory sequence is operably linked to a nucleic acid sequence encoding a miRl 55 gene product.
- transgene refers to a nucleic acid sequence introduced into one or more cells of a non-human animal by way of human intervention, such as by way of the methods described herein.
- the introduced genetic information may be foreign to the species of animal to which the recipient belongs, foreign only to the particular individual recipient, or genetic information already possessed by the recipient.
- the transgenic non-human animals have a genome that comprises a nucleic acid construct/transgene, that is capable of expressing a miR155 gene product.
- miR gene products also referred to herein as microRNAs, miRs and miRNAs
- miR gene product does not include proteins.
- the unprocessed miR gene transcript is also called a "miR precursor," and typically comprises an RNA transcript of about 70-100 nucleotides in length.
- the miR precursor can be processed (e.g., through natural processing routes (e.g., using intact cells or cell lysates) or by synthetic processing routes (e.g., using isolated processing enzymes, such as isolated Dicer, Argonaut, or RNAse III (e.g., E. coli RNAse III)) into an active 19-25 nucleotide RNA molecule.
- This active 19-25 nucleotide RNA molecule is also called the "processed" miR gene transcript or "mature" miRNA.
- a microRNA is referred to herein by name, the name corresponds to both the precursor and mature forms, unless otherwise indicated.
- miR155 gene product refers to the unprocessed (e.g., precursor) or processed (e.g., mature) RNA transcript from a miR155 gene, such as, but not limited to, a miR155 gene from mouse (Mus musculus).
- the precursor miR155 gene product from mouse is represented by the nucleotide sequence: 5'-
- the miR155 gene product comprises a nucleotide sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100%, sequence identity to the nucleotide sequences of SEQ ID NO:1 and/or SEQ ID NO:2.
- the miR155 gene product comprises a nucleotide sequence having 100% identity to the nucleotide sequence of SEQ ID NO:1.
- the miR155 gene product comprises a nucleotide sequence having 100% identity to the nucleotide sequence of SEQ ID NO:2.
- the database searched is a non-redundant (NR) database
- parameters for sequence comparison can be set at: no filters; Expect value of 10; Word Size of 3; the Matrix is BLOSUM62; and Gap Costs have an Existence of 11 and an Extension of 1.
- the percent identity between two amino acid sequenees can be accomplished using the GAP program in the GCG software package (Accelrys, San Diego, California) using either a Blossom 63 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4, and a length weight of 2, 3, or 4.
- the percent identity between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package (Accelrys, San Diego, California), using a gap weight of 50 and a length weight of 3.
- the transgenic non-human animal possesses a genome that comprises a nucleic acid construct in which a nucleic acid sequence encoding a miR155 gene product is operably linked to at least one transcriptional regulatory sequence capable of directing expression in B cells of the animal.
- transcriptional regulatory sequence is used according to its art-recognized meaning. It is intended to mean any DNA sequence that can, by virtue of its sequence, cause the linked gene to be either up- or down-regulated in a particular cell. In the case of a promoter, the promoter will generally be adjacent to the coding region.
- the enhancer may function at some distance from the coding region, such that there is an intervening DNA sequence between the enhancer and the coding region.
- the genetic information which may include a DNA sequence encoding a particular protein (or "coding region")
- the coding region of interest may be coupled to at least one transcriptional regulatory sequence in a functional manner.
- Transcriptional regulatory sequences may be used to increase, decrease, regulate or designate to certain tissues or to certain stages of development, the expression of a gene.
- the transcriptional regulatory sequences need not be naturally occurring sequences.
- a sequence encoding miR155 is operably linked to transcriptional regulatory sequence(s) directing expression to B cells, to generate a recombinant construct or transgene.
- the transcriptional regulatory sequence can be any sequence capable of directing expression in B cells. Examples of suitable transcriptional regulatory sequence include, but are not limited to, a V H promoter, an Ig heavy chain-E ⁇ enhancer and a combination thereof.
- the transcriptional regulatory sequence is a mouse transcriptional regulatory sequence or a transcriptional regulatory sequence derived from mouse.
- a nucleic acid molecule is said to be “capable of expressing” or “capable of directing expression of a microRNA if it contains nucleotide sequence(s) that contain transcriptional regulatory information, and such sequence(s) are “operably linked” to nucleotide sequence(s) that encode the microRNA.
- An operable linkage is a linkage in which regulatory nucleic acid sequence(s) and the nucleic acid sequence(s) sought to be expressed are connected in such a way as to permit gene expression.
- the regulatory regions needed for gene expression include, but are not limited to, transcriptional regulatory sequences (e.g., a promoter region, an enhancer region), as well as DNA sequence(s) that, when transcribed into RNA, contribute to the stability of the gene transcript.
- transcriptional regulatory sequences e.g., a promoter region, an enhancer region
- DNA sequence(s) that, when transcribed into RNA, contribute to the stability of the gene transcript.
- promoter is used according to its art-recognized meaning. It is intended to mean the DNA region, usually upstream to the coding sequence of a gene or operon, which binds RNA polymerase and directs the enzyme to the correct transcriptional start site. A promoter region is operably linked to a DNA sequence if the promoter is capable of effecting transcription of that DNA sequence.
- enhancer is used according to its art-recognized meaning. It is intended to mean a sequence found in eukaryotes and certain eukaryotic viruses, which can increase transcription from a gene when located (in either orientation) up to several kilobases from the gene being studied. These sequences usually act as enhancers when on the 5' side (upstream) of the gene in question. However, some enhancers are active when placed on the 3' side (downstream) of the gene. In some cases, enhancer elements can activate transcription from a gene with no (known) promoter.
- the nucleic acid construct may also include sequences that promote expression and/or stability of the construct and/or a gene product expressed from the construct.
- the nucleic acid construct comprises the 3' UTR and poly(A) sequence of a ⁇ -globin gene (e.g., a mouse ⁇ -globin gene).
- a ⁇ -globin gene e.g., a mouse ⁇ -globin gene.
- Other sequences that promote expression and/or stability of the construct and/or a gene product expressed from the construct are known in the art and are encompassed herein.
- transgenic non-human animal is used herein to include all vertebrate animals, except humans.
- the transgenic non-human animal is a mammal.
- Such transgenic non-human animals include, for example, transgenic pigs, transgenic rats, transgenic rabbits, transgenic cattle, transgenic goats, and other transgenic animal species, particularly mammalian species.
- other members of the rodent family e.g., rats, and guinea pigs, and nonhuman primates, such as chimpanzees, may be used to practice the embodiments described herein.
- the transgenic non-human animal is a mouse.
- the transgenic non-human animals described herein include individual animals in all stages of development, including embryonic and fetal stages.
- a "transgenic animal” is an animal containing one or more cells bearing genetic information received, directly or indirectly, by deliberate genetic manipulation at a subcellular level, such as by microinjection or infection with a recombinant virus.
- the introduced nucleic acid molecule may be integrated within a chromosome, or it may be extra-chromosomally replicating DNA.
- Suitable transgenic animals described herein include, but are not limited to, those animals in which the genetic information was introduced into a germ line cell, thereby conferring the ability to transfer the information to offspring. If such offspring in fact possess some or all of that information, then they, too, are transgenic animals.
- any method known in the art for introducing a recombinant construct or transgene into an embryo such as, for example, microinjection, use of a cell gun, transfection, liposome fusion, electroporation, and the like, may be used.
- the method for producing a transgenic animal is microinjection, which involves injecting a DNA molecule into the male pronucleus of a fertilized egg (see, e.g., U.S. Pat. Nos. 4,870,009; 5,550,316; 4,736,866; and 4,873,191). Methods for introducing a recombinant construct/transgene into mammals and their germ cells were originally developed in the mouse.
- the methods for evaluating the presence of the introduced transgene as well as its expression are readily available and well-known in the art. Such methods include, but are not limited to, DNA (Southern) hybridization to detect the exogenous DNA, polymerase chain reaction (PCR), polyacrylamide gel electrophoresis (PAGE) and blots to detect DNA, RNA or protein.
- DNA Southern
- PCR polymerase chain reaction
- PAGE polyacrylamide gel electrophoresis
- blots to detect DNA, RNA or protein.
- transgenic mice can be produced.
- Other non-limiting examples include, e.g., other non-human mammals described herein, such as guinea pigs, rabbits, pigs, sheep, etc.
- the success rate for producing transgenic animals by microinjection is highest in mice, where approximately 25% of fertilized mouse eggs into which the DNA has been injected, and which have been implanted in a female, will develop into transgenic mice. Lower success rates have been achieved with rabbits, pigs, sheep and cattle.
- the transgenic non-human animals described herein exhibit an expanded population of B220 low /CD19 low /CD10 Iow / TgM7TCR7CD43 " lymphoid cells in the spleen, the bone marrow or both the spleen and bone marrow, relative to this population in a suitable control animal.
- B220 low /CD19 low /CD10 low /IgM " /TCR7CD43 ' cells” refers to a population of lymphoid cells that represents an increase in the number of B220 low /CD19 low /CDl ⁇ 'T/TgM7TCR7CD43- cells and/or the proportion of B220 low /CD19 low /CD10 low /IgM7TCR7CD43 " cells relative to other subtypes of lymphoid cells, as compared to that of a control animal.
- the transgenic non-human animals described herein exhibit a lymphoprol ⁇ ferative condition.
- “Lymphoproliferative” refers to that which pertains to, or is characterized by, proliferation of the cells of the lymphoreticular system; the term is generally used to refer to a group of malignant neoplasms.
- “Lymphoreticular” refers to the cells or tissues of both the lymphoid and reticuloendothelial systems.
- Lymphoproliferative condition refers to one of a group of malignant neoplasms arising from cells related to the common multipotential, primitive lymphoreticular cell that includes, among others, the lymphocytic, histiocytic, and monocytic leukemias, multiple myeloma, plasmacytoma, Hodgkin's disease, all lymphocytic lymphomas, and immunosecretory disorders associated with monoclonal gammopathy.
- lymphoproliferative disorder may also refer to a physiological state in which the proliferation, multiplication and/or accumulation of cells of the lymphoreticular system is altered relative to a normal or control animal, but the affected animal does not yet necessarily exhibit symptoms of one of the neoplasms described above.
- a "preleukemic” state refers to such a lymphoproliferative condition that precedes the development of overt symptoms of leukemia.
- the lymphoproliferative condition is a B cell malignancy (e.g., a B cell leukemia (for example, acute lymphoblastic leukemia); a B cell lymphoma (e.g., high-grade lymphoma), a B cell neoplasm).
- the B cell malignancy exhibits characteristics of human acute lymphoblastic leukemia, human lymphoblastic lymphoma or a combination thereof.
- the lymphoproliferative condition is a preleukemic state (e.g., pre-B cell proliferation).
- the transgenic non-human animal exhibits an enlarged abdomen, splenomegaly, bone marrow replacement, lymphopenia, or a combination thereof.
- lymphoproliferative disorders e.g., B cell malignancies (e.g., leukemias (e.g., acute lymphoblastic leukemia), lymphomas (e.g., high-grade lymphoma), and neoplasms)
- lymphoproliferative disorders e.g., B cell malignancies (e.g., leukemias (e.g., acute lymphoblastic leukemia), lymphomas (e.g., high-grade lymphoma), and neoplasms)
- lymphoproliferative disorders e.g., B cell malignancies (e.g., leukemias (e.g., acute lymphoblastic leukemia), lymphomas (e.g., high-grade lymphoma), and neoplasms)
- B cell malignancies e.g., leukemias (e.g., acute lymphoblastic leukemia), lymphomas (e.g., high-grade lympho
- the method comprises administering the agent to a transgenic non-human animal (e.g., a mouse) described herein.
- the transgenic non-human animal has a genome comprising a nucleic acid construct that comprises at least one transcriptional regulatory sequence capable of directing expression in B cells of the animal (e.g., a V H promoter, an Ig heavy chain-E ⁇ enhancer, a combination thereof), wherein the transcriptional regulatory sequence is operably linked to a nucleic acid encoding a miR.155 gene product.
- the transcriptional regulatory sequence is operably linked to a nucleotide sequence having at least 90% sequence identity to SEQ ID NO: 1 and/or SEQ ID NO:2.
- the miR155 gene product comprises the nucleotide sequence of SEQ ID NO: 1.
- the miRl 55 gene product comprises the nucleotide sequence of SEQ ID NO:2.
- one or more symptoms and/or indications of the lymphoproliferative condition in the transgenic animal are compared with those of a control animal of the same genotype, which has not been administered the agent. If the agent inhibits, prevents and/or reduces one or more symptoms and/or indications of the lymphoproliferative condition in the transgenic animal to which it has been administered, relative to the control animal, then the agent is considered to have therapeutic efficacy in treating or preventing a lymphoproliferative condition.
- the one or more symptoms and/or indications of the lymphoproliferative condition are selected from the group consisting of: an expanded population of B220 low /CD19 low /CD10 low / IgM " /TCR7CD43 " lymphoid cells, enlarged abdomen, splenomegaly, bone marrow replacement, lymphopenia and a combination thereof.
- lymphoproliferative conditions that are suitable for testing the therapeutic efficacy of an agent include, for example, those described herein.
- the lymphoproliferative condition is a B cell malignancy.
- the B cell malignancy is selected from the group consisting of acute lymphoblastic leukemia, B cell lymphoma (e.g., high-grade lymphoma), B cell neoplasm and a combination thereof.
- the B cell malignancy may exhibit characteristics of human acute lymphoblastic leukemia, human lymphoblastic lymphoma or both.
- the lymphoproliferative condition is a preleukemic state, such as a state characterized by pre-B cell proliferation.
- transgenic non-human animals that express miRl 55 in B cells.
- a transgenic animal whose genome comprises a nucleic acid construct or transgene comprising at least one transcriptional regulatory sequence capable of directing expression to B cells, wherein the transcriptional regulatory sequence is operably linked to a nucleic acid sequence encoding miRl 55.
- the transgene comprises a DNA sequence encoding miRl 55 which has been placed under the transcriptional control of a VH promoter and/or an Ig heavy chain-E ⁇ enhancer.
- mirl55 expression is directed to immature and mature B cells.
- the transgenic animals are mice which develop an expanded population of B220 low /CD19 low /CD10 low /IgM ' /TCR7CD43 " lymphoid cells.
- white blood cells from a transgenic animal exhibiting lymphoproliferation may be transferred to a second animal (which may be a non-transgenic animal), thereby inducing a rapid onset of lymphoproliferative disease in the second "recipient" animal.
- potential therapeutic modalities or agents for preventing and/or treating lymphoproliferative disorders may be tested by measuring the anti-lymphoproliferative activity of such modalities in animals produced according to one or more aspects as described herein. Such activity may be assessed by measuring the capacity of a potential therapeutic modality to inhibit, prevent, and/or destroy one or more of the symptoms or indications of lymphoproliferative disease exhibited by transgenic animals produced according to one embodiment and/or in "recipient" animals produced according to another embodiment.
- agents can be individually screened or one or more agents can be tested simultaneously. Where a mixture of compounds is tested, the compounds selected by the processes described can be separated (as appropriate) and identified using suitable methods (e.g., sequencing, chromatography). The presence of one or more compounds in a test sample can also be determined according to these methods.
- lymphoproliferative disorders can be identified, for example, by screening libraries or collections of molecules, such as, the Chemical Repository of the National Cancer Institute, in assays that measure inhibition and/or prevention of one or more of the symptoms or indications of lymphoproliferative disease exhibited by the transgenic animals described herein.
- Libraries such as combinatorial libraries, of compounds (e.g., organic compounds, recombinant or synthetic peptides, "peptoids", nucleic acids) produced by combinatorial chemical synthesis or other methods can be tested (see e.g., Zuckerman, R.N. et al, J. Med.
- Identified therapeutic modalities can further be formulated in accordance with known methods to produce pharmaceuticaJly-acceptable compositions.
- Therapeutic modalities or compositions comprising such therapeutic modalities may be administered to subjects (e.g., transgenic animals) in a variety of standard ways.
- the agent can be administered using a variety of routes, including, for example, oral, dietary, topical, transdermal, rectal, parenteral (e.g., intravenous, intraarterial, intramuscular, subcutaneous, intradermal injection), and inhalation (e.g., intrabronchial, intranasal, oral inhalation, intranasal drops).
- Administration can be local or systemic as indicated.
- the preferred mode of administration can vary depending upon the antibody or antigen-binding fragment to be administered and the particular condition (e.g., disease) being treated, however, oral or parenteral administration is generally preferred.
- Agents can be administered parenterally such as, for example, by intravenous, intramuscular, intrathecal or subcutaneous injection.
- Parenteral administration can be accomplished by incorporating the agent(s) into a solution or suspension.
- solutions or suspensions may also include sterile diluents, such as water for injection, saline solution, bacteriostatic saline (saline containing about 0.9% mg/ml benzyl alcohol), phosphate- buffered saline (referred to herein as PBS), Hank's solution, Ringer's-lactate, fixed oils, polyethylene glycols, glycerine, propylene glycol, and other synthetic solvents.
- sterile diluents such as water for injection, saline solution, bacteriostatic saline (saline containing about 0.9% mg/ml benzyl alcohol), phosphate- buffered saline (referred to herein as PBS), Hank's solution, Ringer's
- Parenteral formulations may also include antibacterial agents (e.g., benzyl alcohol, methyl parabens), antioxidants (e.g., ascorbic acid, sodium bisulfite), and chelating agents (e.g., EDTA).
- antibacterial agents e.g., benzyl alcohol, methyl parabens
- antioxidants e.g., ascorbic acid, sodium bisulfite
- chelating agents e.g., EDTA
- Buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride and dextrose, may also be added.
- the parenteral preparation can be enclosed in ampules, disposable syringes, or multiple dose vials made of glass or plastic.
- Example 1 Production of E ⁇ -mmu-miRl 55 transgenic mice.
- a 318-bp fragment containing the precursor sequence of miRl 55 was amplified by PCR from the genome of the 129SvJ mouse (The Jackson Laboratory) and cloned into the EcoRV and Sail sites of the pBSVE6BK (pE ⁇ ) plasmid, which contains the E ⁇ enhancer VH promoter for Ig heavy chains and the 3' UTR and the po!y(A) of the human ⁇ - globin gene (FIG. 1), and had been used previously for the development of chronic lymphocytic leukemia in E ⁇ -TCLl transgenic mice (Bichi, R., et al, Proc. Natl. Acad. Sci. USA 99:6955-6960 (2002)).
- transgene which was isolated by cutting the construct with BssHII and Pvul, was injected into the male pronucleus of fertilized oocytes of pregnant FVB/N and C57/B6 mice. Pups were screened for the presence of the transgene by Southern blot analysis, which was performed on tail-extracted DNA that was digested with BamHI, using a probe designed to target the E ⁇ enhancer sequence (FIGS. 2A, 2B). Transgenic founders were identified and bred to age-matched wild-type mice. Transgenic hemizygous mice were born, studied, and compared with their wild-type counterparts. Mice were genotyped by PCR performed on tail-extracted DNA (data not shown).
- the membrane was hybridized with a ⁇ - 32 P radioactive probe containing the antisense of the mature mmu- miR155 sequence, incubated overnight, washed, and exposed to a Phosphor Imager screen (Molecular Dynamics). The image was processed using a Typhoon image processing system (Amersham Biosciences) (FIG. 3).
- Transgenic mice were generated in which mmu-miRl 55 (mouse miRl 55) expression is under the control of a V H promoter-Ig heavy chain E ⁇ enhancer, which becomes active at the late pro-B cell stage of B cell development.
- Fifteen transgenic founders were identified by Southern blot hybridization (FIGS. 2A, 2B), seven on a C57BL/B6 background (designated F1-F7) and eight on an FVB/N background (designated F8-F15). These founders were bred to wild-type mice of the same strain to produce 15 independent transgenic lines.
- Example 2 Phenotypic characterization of E ⁇ -mmu-miR 155 transgenic mice reveals a pre-B cell proliferation in spleens and bone marrow, leading to B cell malignancies.
- mice were weighed after being killed, and their spleens were dissected, measured and weighed.
- WBC White blood cell
- mice The bodies and spleens of transgenic mice were enlarged relative to the spleens of wild-type mice (FIGS. 4A, 4B), with a spleen weight/body weight ratio three to four times greater than the ratio of wild-type mice (Table 1). Interestingly, the ratio did not vary much with age. [000102] Table 1. Spleen and body measurements for transgenic and wild-type mice.
- the white blood cell count (WBC) of 3-month-old transgenic mice was 10 X 10 6 ⁇ 1 X 10 6 per ml of peripheral blood, compared with 40 X 10 6 ⁇ 1.5 X 10 6 per ml of peripheral blood for normal, age-matched mice.
- the WBC for transgenic mice at 6 months of age was even lower, with a value of 6 X 10 6 ⁇ 0.5 X 10 6 per ml of peripheral blood compared with an unchanged value of 40 X 10 6 ⁇ 1.5 X 10 6 per ml of peripheral blood for wild-type, age-matched mice.
- mice at 6 months of age presented a greatly increased malignant lymphoid population with marked atypia and blastic appearance, proliferating in the vascular channels of the red pulp and gradually replacing the white pulp.
- the number of germinal follicles was decreased, and the overall architecture of the spleen was distorted by lymphoid proliferation (FIG. 5B).
- a histologically-similar lymphoid population was present in the bone marrow of 6-month-old mice.
- Expression of the proliferation antigen, Ki67 showed a marked lymphoid proliferation in transgenic mice (FIG. 5D), which was not observed in wild-type mice.
- Example 3 Cytogenetic analysis of E ⁇ -mmu-miR155 transgenic mice.
- Femur bone marrow was flushed with RPMI medium 1640/20% FBS and collected into 5 ml of RPM ⁇ medium 1640/20% FBS with 1% heparin. Cells were grown and assessed for chromosomal deletions, translocations, inversions, and number of metaphases using standard cytological techniques.
- a probe was designed by amplifying a sequence in the JH4 fragment of the Ig heavy chain region of mouse genomic DNA using the following oligonucleotide primers: forward, 5 '-TG AAGG ATCTGCC AG AACTGAA-3' (SEQ ID NO:3) 5 and reverse, 5'- TGCAATGCTCAGAAAACTCCAT-S 1 (SEQ ID NO:4).
- Spleens of the transgenic and wild-type mice were dissociated between frosted slides in PBS, treated with ammonium chloride to lyse erythrocytes, centrifuged, and resuspended in PBS.
- DNA was extracted from white blood cells of the spleens and digested with EcoRJ, Stul, BgIII, BamHI, and HindIIL Digested DNA was blotted on a Hybond N + membrane, hybridized with the JH4 probe, which was radioactively labeled with ⁇ - 32 P, and then exposed to a Phosphorlmager screen and processed using a Typhoon scanner.
- miR155 has been observed in solid tumors, such as breast and colon cancer, as well as lung cancers, where overexpression of miR155 was an indicator of poor prognosis (Volinia, S., et al., Proc. Natl. Acad. Sci. USA 103:2257- 2261 (2006)).
- Example 4 Microarray expression profiling reveals up-regulation of VpreB 1 mRNA and other targets
- RNA isolation was performed with the TRIzol reagent (Invitrogen), according to the manufacturer's instructions.
- RNA labeling and hybridization on miRNA microarray chips were performed as described (Liu, C.G., et al, Proc. Natl. Acad. ScL USA 101:9740-9744). Briefly, 5 ⁇ g of total RNA from each sample were labeled with biotin by reverse transcription using 5' biotin end- labeled random octamer oligonucleotide primers. Hybridization of biotin- labeled cDNA was carried out on a miRNA microarray chip (Ohio State University, Ver. 2.0), which contains 800 miRNA probes, including 245 human and 200 mouse miRNA genes, in quadruplicate.
- Hybridization signals were detected by binding of a Streptavidin- Alexa647 conjugate to biotin using Axon Scanner 4000B (Axon Instruments, Union City, CA). The images were quantified by GENEPIX 6.0 software (Axon Instruments).
- mRNA Expression Profiling [000128] GeneChip Mouse genome 430 2.0 arrays (Affymetrix), containing probe sets for greater than 45,000 characterized genes and expressed sequence tags, were used. Sample labeling and processing, GeneChip hybridization, and scanning were performed according to Affymetrix protocols. Briefly, double-stranded cDNA was synthesized from total RNA using the Superscript Choice System (Invitrogen), which adds a T7 RNA polymerase promoter site to the 3'-end (Genset, La Jolla, CA). Biotinylated cRNAs were generated from cDNAs in vitro and amplified using the BioArray T7 RNA polymerase labeling kit (Enzo Diagnostics).
- cRNA was fragmented at 94 0 C for 35 min. Approximately 12.5 ⁇ g of fragmented cRNA was used in a 250- ⁇ l hybridization mixture containing herring-sperm DNA (0.1 mg/ml; Promega), plus bacterial and phage cRNA controls (1.5 pM BioB, 5 pM BioC, 25 pM BioD, and 100 pM Cre) to serve as internal controls for hybridization efficiency. Aliquots (200 ⁇ l) of the mixture were hybridized to arrays for 18 hours at 45°C in a GeneChip Hybridization Oven 640 (Affymetrix).
- Each array was washed and stained with streptavidin— phycoerythrin (Tnvitrogen) and amplified with biotinylated antistreptavidin antibody (Vector Laboratories) on the GeneChip Fluidics Station 450 (Affymetrix). Arrays were scanned with the GeneArray G7 scanner (Affymetrix) to obtain image and signal intensities.
- Microarray analysis was performed on total RNA extracted from the splenic white blood cells of five transgenic mice, including one mouse that did not express the miR155 transgene, and the white blood cells of six wild-type littermate counterparts.
- the analysis revealed a 10- to 20-fold increase in the expression ofmiR155, miR194, miR224, miR217, and miR151 (Table 3), and a 2- to 3-fold decrease in the expression of miR146 and miR138, in transgenic mice that overexpress miR155, relative to the wild-type littermate control mice (data not shown).
- Affymetrix microarray chip the differential expression of mRNAs in the same group of transgenic mice was studied and compared with mRNA expression in the littermate controls.
- Affymetrix microarray data showed that 200 proliferation-associated genes were up- regulated, whereas 50 genes were down-regulated in the miR155-overexpressing mice (Table 3). Notably, VpreBl mRNA was upregulated, which is expected to occur when the proliferation of pre-B cells takes place. These data complement the data from flow cytometry analysis and immunohistochemistry. 131] Table 2. Affymetrix microarray data for miR155 transgenic/wild-type mouse classification based on Prediction Analysis of Microarrays (PAM). mirl55
- member 12 /// killer cell lectin-like receptor, subfamily A.
- member 4 /// killer cell lectin-like receptor, subfamily A 5
- member 7 /// killer cell lectin-like receptor subfamily A
- member 20 /// killer cell lectin-like receptor, subfamily A.
- Fc receptor IgE, low affinity II
- T-cell receptor beta variable 13 /// similar to TCRB V7S 1 /// similar to
- the mirl55 mRNA signature * indicates the genes that are over-expressed in mouse mirl55, # indicates the genes that are under-expressed.
- the score is the PAM score (Tibshirani, R. J., Hastie, T. J., Narasimhan, B., and Chu, G. (2002), "Diagnosis of multiple cancer types by shrunken centroids of gene expression," Proceedings of the National Academy of Sciences, 99, 6567-6572).
- PAM's method of "nearest shrunken centroids” identifies the subsets of genes that best characterize the mirl55 transgene. PAM's score is not a fold change.
- Table 3 Affymetrix microarray data depicting signature of microRNAs that are significantly over-expressed in mirl55 transgenic mice based on Prediction Analysis of Microarrays (PAM) classification (5 transgenic mice and 6 wild-type mice).
- PAM Microarrays
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74545406P | 2006-04-24 | 2006-04-24 | |
PCT/US2007/009910 WO2007127190A2 (en) | 2006-04-24 | 2007-04-24 | Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2023944A2 true EP2023944A2 (en) | 2009-02-18 |
EP2023944A4 EP2023944A4 (en) | 2011-10-05 |
Family
ID=38656133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07776079A Withdrawn EP2023944A4 (en) | 2006-04-24 | 2007-04-24 | Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice |
Country Status (7)
Country | Link |
---|---|
US (1) | US7667090B2 (en) |
EP (1) | EP2023944A4 (en) |
JP (1) | JP5127821B2 (en) |
CN (1) | CN101472470B (en) |
AU (1) | AU2007243475B2 (en) |
CA (1) | CA2650026C (en) |
WO (1) | WO2007127190A2 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5489459B2 (en) * | 2005-08-01 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | MicroRNA-based methods and compositions for diagnosis, prognosis and treatment of breast cancer |
WO2007033023A2 (en) * | 2005-09-12 | 2007-03-22 | The Ohio State University Research Foundation | Compositions and methods for the diagnosis and therapy of bcl2-associated cancers |
JP2009511482A (en) * | 2005-10-05 | 2009-03-19 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | WWOX gene, vectors containing the same, and use in the treatment of cancer |
EP2586454B1 (en) | 2006-01-05 | 2014-10-08 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
ES2465600T3 (en) | 2006-01-05 | 2014-06-06 | The Ohio State University Research Foundation | Methods based on microRNA and compositions for the diagnosis and treatment of solid cancers of the pancreas |
ES2554531T3 (en) * | 2006-01-05 | 2015-12-21 | The Ohio State University Research Foundation | Procedures based on microRNAs for the diagnosis, prognosis and treatment of lung cancer |
WO2007109236A2 (en) | 2006-03-20 | 2007-09-27 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
CN101657547B (en) | 2006-07-13 | 2016-04-27 | 俄亥俄州立大学研究基金会 | For the diagnosis and treatment of the method and composition based on Microrna of colon cancer-related diseases |
US8071292B2 (en) | 2006-09-19 | 2011-12-06 | The Ohio State University Research Foundation | Leukemia diagnostic methods |
CA2667617A1 (en) | 2006-11-01 | 2008-05-08 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
EP2109687B1 (en) * | 2007-01-31 | 2014-06-04 | The Ohio State University Research Foundation | Micro-rna-based methods for the treatment of acute myeloid leukemia |
EP2142659A4 (en) * | 2007-04-30 | 2010-06-09 | Univ Ohio State Res Found | Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis |
AU2008262252B2 (en) | 2007-06-08 | 2013-09-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells |
US8053186B2 (en) | 2007-06-15 | 2011-11-08 | The Ohio State University Research Foundation | Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing |
EP2808398A1 (en) | 2007-07-31 | 2014-12-03 | The Ohio State University Research Foundation | Methods for reverting methylation by targeting DNMT3A and DNMT3B |
ES2627059T3 (en) * | 2007-08-03 | 2017-07-26 | The Ohio State University Research Foundation | Ultraconserved regions encoding RNAnc |
CA2926831A1 (en) * | 2007-08-22 | 2009-02-26 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
EP2183393B1 (en) * | 2007-09-06 | 2014-06-11 | The Ohio State University Research Foundation | Microrna signatures in human ovarian cancer |
CN103937876B (en) * | 2007-10-11 | 2016-08-17 | 俄亥俄州立大学研究基金会 | For diagnosing and treat the method and composition of adenocarcinoma of esophagus |
US8911998B2 (en) | 2007-10-26 | 2014-12-16 | The Ohio State University | Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof |
JP2011505143A (en) * | 2007-11-30 | 2011-02-24 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | MicroRNA expression profiling and peripheral blood targeting in lung cancer |
CN104031984A (en) * | 2008-02-28 | 2014-09-10 | 俄亥俄州立大学研究基金会 | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders |
JP2011517932A (en) * | 2008-02-28 | 2011-06-23 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | MicroRNA signatures associated with human chronic lymphocytic leukemia (CCL) and uses thereof |
CN102149827B (en) | 2008-06-11 | 2014-08-20 | 由卫生与公众服务部代表的美利坚合众国政府 | Use of MiR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy |
JP5960060B2 (en) | 2009-11-23 | 2016-08-02 | ジ・オハイオ・ステート・ユニバーシティ | Substances and methods useful for influencing tumor cell growth, migration and invasion |
CA2794142A1 (en) * | 2010-03-26 | 2011-09-29 | The Ohio State University | Materials and methods related to modulation of mismatch repair and genomic stability by mir-155 |
CA2802738A1 (en) * | 2010-06-24 | 2011-12-29 | The Ohio State University | Chronic lymphocytic leukemia modeled in mouse by targeted mir-29 expression |
WO2012065049A1 (en) | 2010-11-12 | 2012-05-18 | The Ohio State University Research Foundation | Materials and methods related to microrna-21, mismatch repair, and colorectal cancer |
CA2817982C (en) | 2010-11-15 | 2020-06-30 | The Regents Of The University Of Michigan | Controlled release mucoadhesive systems |
KR101382219B1 (en) * | 2010-12-23 | 2014-04-08 | 경희대학교 산학협력단 | Transgenic mouse overexpressing microRNA―24 as a model of mitochondrial dysfunction―associated diseases |
CN102120038A (en) * | 2011-02-12 | 2011-07-13 | 华侨大学 | Gene treatment medicament capable of inhabiting immunoreaction caused by transgenosis products and preparation method thereof |
CN103561750A (en) | 2011-03-07 | 2014-02-05 | 俄亥俄州立大学 | Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer |
CN104364390B (en) | 2011-10-14 | 2016-08-24 | 俄亥俄州立大学 | The method relevant to ovarian cancer and material |
CN104619353A (en) | 2011-12-13 | 2015-05-13 | 俄亥俄州国家创新基金会 | Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis |
US9402376B2 (en) * | 2012-01-13 | 2016-08-02 | Advanced Genomic Technology, Llc | Transgenic mice expressing microRNA34 that have cells displaying increased senescence and apoptosis |
CN104685065B (en) | 2012-01-20 | 2017-02-22 | 俄亥俄州立大学 | Breast cancer biomarker signatures for invasiveness and prognosis |
EP3224381B1 (en) | 2014-11-25 | 2019-09-04 | The Brigham and Women's Hospital, Inc. | Method of identifying a person having a predisposition to or afflicted with a cardiometabolic disease |
EP3224380A1 (en) | 2014-11-25 | 2017-10-04 | The Broad Institute Inc. | Clonal haematopoiesis |
US20180084766A1 (en) * | 2015-04-07 | 2018-03-29 | The Children's Medical Center Corporation | Methods and compositions relating to an embryonic stem cell-based tumor model |
CN106754699B (en) * | 2016-12-22 | 2020-01-31 | 朗姿赛尔生物科技(广州)有限公司 | Application of miRNA-155 and inhibitor thereof in DC-CIK cell culture |
CN107760765A (en) * | 2017-11-29 | 2018-03-06 | 河南农业大学 | A kind of method for detecting pig ADD2 gene expression amounts and application |
CN112574994B (en) * | 2020-12-17 | 2023-10-24 | 河南牧业经济学院 | Method for screening active region of pig miR-155 gene promoter and transcriptional regulatory element |
WO2024047115A1 (en) | 2022-09-02 | 2024-03-07 | Leibniz-Institut Für Immuntherapie (Lit) | THERAPEUTIC USE OF THE miR155 SNP rs377265631 |
-
2007
- 2007-04-24 WO PCT/US2007/009910 patent/WO2007127190A2/en active Application Filing
- 2007-04-24 CA CA2650026A patent/CA2650026C/en not_active Expired - Fee Related
- 2007-04-24 US US12/298,221 patent/US7667090B2/en not_active Expired - Fee Related
- 2007-04-24 EP EP07776079A patent/EP2023944A4/en not_active Withdrawn
- 2007-04-24 AU AU2007243475A patent/AU2007243475B2/en not_active Ceased
- 2007-04-24 JP JP2009507755A patent/JP5127821B2/en not_active Expired - Fee Related
- 2007-04-24 CN CN2007800230938A patent/CN101472470B/en not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
COSTINEAN S ET AL: "Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E.mu.-miR155 transgenic mice", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, WASHINGTON, DC; US, vol. 103, no. 18, 2 May 2006 (2006-05-02), pages 7024-7029, XP008124258, ISSN: 0027-8424, DOI: 10.1073/PNAS.0602266103 [retrieved on 2006-04-25] * |
Michelle Gailiun, Medical Center Communications: "SINGLE microRNA CAUSES CANCER IN TRANSGENIC MOUSE", Research communications. The Ohio State University , 17 April 2006 (2006-04-17), XP000002657438, Retrieved from the Internet: URL:http://researchnews.osu.edu/archive/newmouse.htm [retrieved on 2011-08-23] * |
See also references of WO2007127190A2 * |
Also Published As
Publication number | Publication date |
---|---|
US7667090B2 (en) | 2010-02-23 |
CA2650026A1 (en) | 2007-11-08 |
US20090222934A1 (en) | 2009-09-03 |
CA2650026C (en) | 2013-01-22 |
EP2023944A4 (en) | 2011-10-05 |
CN101472470B (en) | 2013-07-24 |
CN101472470A (en) | 2009-07-01 |
WO2007127190A3 (en) | 2008-04-17 |
AU2007243475B2 (en) | 2013-02-07 |
WO2007127190A2 (en) | 2007-11-08 |
AU2007243475A1 (en) | 2007-11-08 |
JP2009534051A (en) | 2009-09-24 |
JP5127821B2 (en) | 2013-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007243475B2 (en) | Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in miR155 transgenic mice | |
Wang et al. | Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene | |
Beachy et al. | Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma | |
Wrabetz et al. | P0 glycoprotein overexpression causes congenital hypomyelination of peripheral nerves | |
Chennathukuzhi et al. | Mice deficient for testis-brain RNA-binding protein exhibit a coordinate loss of TRAX, reduced fertility, altered gene expression in the brain, and behavioral changes | |
Neesen et al. | Disruption of an inner arm dynein heavy chain gene results in asthenozoospermia and reduced ciliary beat frequency | |
US20130139273A1 (en) | Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted miR-29 Expression | |
Snyder et al. | APOBEC1 complementation factor (A1CF) is dispensable for C-to-U RNA editing in vivo | |
McIntyre et al. | Emx2 stimulates odorant receptor gene expression | |
WO2009048747A2 (en) | Candidate genes and blood biomarkers for bipolar mood disorder, alcoholism and stress disorder | |
WO2006095559A1 (en) | USE OF Fgf21 AS HEMATOPOIETIC FACTOR | |
KR101223660B1 (en) | Pharmaceutical Compositions for Preventing or Treating Arthritis Comprising HIF-2α Inhibitor as an Active Ingredient | |
WO2007012970A1 (en) | Graded expression of snail as marker of cancer development and dna damage-based diseases | |
Chen et al. | Promotion of bronchopulmonary dysplasia progression using circular RNA circabcc4 via facilitating PLA2G6 expression by sequestering miR-663a | |
Hosur et al. | Retrotransposon insertion in the T-cell acute lymphocytic leukemia 1 (Tal1) gene is associated with severe renal disease and patchy alopecia in Hairpatches (Hpt) mice | |
Hager et al. | Genetic ablation of Bcl-x attenuates invasiveness without affecting apoptosis or tumor growth in a mouse model of pancreatic neuroendocrine cancer | |
CN110804657A (en) | Application of DIP2C gene in congenital heart disease diagnosis product | |
WO2006105602A1 (en) | Animal models and cells with a modified gene encoding transthyretin-related protein and applications thereof | |
EP2827706B1 (en) | Transgenic animal model of mood disorders | |
CN110511994B (en) | Application of miRNA-4769-3p and homologue thereof | |
JP2006320201A (en) | Method for ameliorating disease symptom caused by mood disorder or related disorder | |
JP2006288387A (en) | Method of ameliorating disease symptom caused by mood disturbance or related disturbance | |
Vicario et al. | Mechanism of neurodegeneration mediated by clonal inflammatory microglia | |
Hu et al. | Matrix attachment regions included in a bicistronic vector enhances and stabilizes follistatin gene expressions in both transgenic cells and transgenic mice | |
JP2014014368A (en) | Biomarker specific for cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081023 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20110906 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 49/00 20060101ALI20110826BHEP Ipc: A01K 67/027 20060101ALI20110826BHEP Ipc: C12N 15/85 20060101ALI20110826BHEP Ipc: A61K 35/74 20060101AFI20110826BHEP |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION |
|
17Q | First examination report despatched |
Effective date: 20150701 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20151112 |